0001140361-24-014226.txt : 20240319
0001140361-24-014226.hdr.sgml : 20240319
20240319214801
ACCESSION NUMBER: 0001140361-24-014226
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240318
FILED AS OF DATE: 20240319
DATE AS OF CHANGE: 20240319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ELMS STEVE
CENTRAL INDEX KEY: 0001250195
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 24766179
MAIL ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 29TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
FORM 4
X0508
4
2024-03-18
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001250195
ELMS STEVE
489 5TH AVENUE
10TH FLOOR
NEW YORK
NY
10017
true
false
Common Stock
2024-03-18
4
S
0
49887
6.01
D
2527500
I
See footnote
Common Stock
2024-03-19
4
S
0
411829
6.08
D
2115671
I
See footnote
Common Stock
76441
D
These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.17. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Includes, as of the transaction date, (i) 24,040 restricted stock units ("RSUs") granted on February 26, 2024 and reported on this Form 4, that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 52,401 shares of common stock owned by the reporting person.
/s/ Steve Elms, by Brian Lenz as Attorney-in-fact
2024-03-19